```html

Immune‑Mediated Hepatitis: A Complete Patient Guide

Overview

Immune‑mediated hepatitis (also called autoimmune hepatitis, AIH) is a chronic inflammatory liver disease in which the body’s own immune system attacks liver cells, causing inflammation and, over time, fibrosis or cirrhosis. Unlike viral hepatitis, there is no infectious agent; the damage is driven by auto‑antibodies and T‑cell–mediated injury.

Who it affects

• Women are affected 3–4 times more often than men.
• Peak incidence occurs between ages 40‑60, but AIH can appear at any age—including in children (≈10 % of cases).
• It occurs worldwide; prevalence estimates range from 10‑20 per 100,000 in North America and Europe to up to 30 per 100,000 in parts of Asia.<sup>[1] Mayo Clinic</sup>

Because the disease often progresses silently, many patients are diagnosed only after routine bloodwork shows abnormal liver enzymes.

Symptoms

Symptoms can be mild, intermittent, or severe. Early disease may be asymptomatic. The most common manifestations include:

General symptoms

• Fatigue – A persistent feeling of tiredness that does not improve with rest.
• Fever – Low‑grade fevers often accompany active inflammation.
• Weight loss – Unintentional loss of 5 % or more of body weight over months.

Gastro‑intestinal symptoms

• Abdominal discomfort – Usually a dull ache in the right upper quadrant.
• Nausea or loss of appetite
• Jaundice – Yellowing of skin and eyes, indicating significant bilirubin elevation.

Physical signs

• Hepatomegaly – Enlarged liver felt on examination.
• Spleen enlargement (splenomegaly) – May occur with portal hypertension.
• Pruritus – Itchy skin caused by bile salts accumulating under the skin.
• Spider angiomas, palmar erythema, or bruising – Signs of chronic liver disease.

Other organ involvement

• Autoimmune overlap syndromes – Some patients also have primary biliary cholangitis or primary sclerosing cholangitis.
• Extra‑hepatic autoimmune diseases – Thyroiditis, rheumatoid arthritis, or type‑1 diabetes are more common in AIH patients.

Because symptoms are non‑specific, any persistent abnormal liver test warrants further evaluation.

Causes and Risk Factors

The exact trigger for immune‑mediated hepatitis remains unknown, but research points to a combination of genetic susceptibility and environmental factors.

Genetic predisposition

• Strong association with certain HLA alleles, especially HLA‑DR3 (DRB1*0301) and HLA‑DR4 (DRB1*0401).<sup>[2] NIH</sup>
• Family clustering occurs in < 5 % of cases, suggesting inherited risk.

Environmental triggers

• Drug‑induced – Certain medications (e.g., minocycline, nitrofurantoin, methyldopa) can provoke an AIH‑like picture.
• Infections – Viral infections (hepatitis A/E, EBV, CMV) have been reported as precipitants, possibly by breaking tolerance.
• Other exposures – Herbals, supplements, or toxins in rare cases.

Risk factors

• Female sex
• Age ≥ 40 years (but remember pediatric cases)
• Presence of other autoimmune disorders
• Family history of autoimmune disease
• Use of implicated medications for > 6 months

Diagnosis

Diagnosing AIH requires a combination of laboratory, imaging, and histologic data. No single test is definitive, so clinicians use scoring systems (International Autoimmune Hepatitis Group criteria). The typical work‑up includes:

Blood tests

• Liver enzymes – ALT and AST are often >10× the upper limit of normal (ULN).
• Immunoglobulin G (IgG) – Elevated in > 80 % of patients.
• Auto‑antibodies
  • Anti‑nuclear antibody (ANA)
  • Smooth muscle antibody (SMA)
  • Liver‑kidney microsomal type 1 antibody (anti‑LKM‑1) – More common in children.
  • Soluble liver antigen/liver pancreas (SLA/LP) – Highly specific.
• Exclusion tests – Hepatitis B & C serology, HIV, and metabolic liver disease panels to rule out other causes.

Imaging

• Ultrasound – Detects liver size, steatosis, or signs of cirrhosis.
• Transient elastography (FibroScan) – Non‑invasive measurement of liver stiffness to estimate fibrosis.
• CT or MRI – Reserved for complications or to rule out focal lesions.

Liver biopsy

Considered the gold standard. Characteristic findings include:

• Interface hepatitis (inflammation at the junction of portal tracts and hepatic lobules).
• Dense lymphoplasmacytic infiltrate.
• Rosette formation of hepatocytes.
• Variable fibrosis ranging from mild to cirrhosis.

Scoring systems

The 1999 International AIH Group (IAIHG) scoring system and the simplified 2008 criteria help clinicians quantify the likelihood of AIH. Scores > 15 (pre‑treatment) or > 17 (post‑treatment) generally confirm the diagnosis.<sup>[3] Cleveland Clinic</sup>

Treatment Options

Timely therapy can induce remission, halt fibrosis, and improve survival (> 95 % 5‑year survival with treatment). Treatment is individualized based on disease severity, age, comorbidities, and pregnancy status.

First‑line medical therapy

• Prednisone (or prednisolone) – Initial dose 30‑60 mg daily; tapered over 6‑12 months once biochemical remission is achieved.
• Azathioprine – Immunomodulator started at 50 mg daily, increased to 1–2 mg/kg; used as a steroid‑sparing agent.

Combination therapy (low‑dose prednisone + azathioprine) is preferred for most adults because it reduces steroid‑related side effects.<sup>[4] WHO</sup>

Second‑line / rescue agents

• Mycophenolate mofetil (MMF) – Effective in patients intolerant to azathioprine.
• Ciclosporin or tacrolimus – Considered for refractory disease.
• Budesonide – A locally acting steroid with fewer systemic effects; useful in non‑cirrhotic patients.

Management of cirrhosis and complications

• Beta‑blockers for portal hypertension.
• Endoscopic variceal ligation if esophageal varices develop.
• Liver transplantation for decompensated cirrhosis or fulminant failure (5‑year post‑transplant survival ≈ 80 %).

Lifestyle and supportive measures

• Alcohol abstinence – Even modest intake can worsen inflammation.
• Balanced diet – Emphasize plant‑based foods, adequate protein, and low‑sodium to support liver health.
• Vaccinations – Hepatitis A & B, influenza, pneumococcal, and COVID‑19.
• Regular monitoring of bone density (steroids increase fracture risk).

Living with Immune‑Mediated Hepatitis

Adjustment to a chronic disease is a journey. Below are practical tips to help maintain health and quality of life.

Medication adherence

• Use a pill organizer or smartphone reminders.
• Never stop steroids abruptly; always taper under medical supervision.
• Report side effects (e.g., nausea, hair loss, infections) promptly.

Routine monitoring

• Blood tests every 2‑4 weeks during induction, then every 3‑6 months once stable.
• Annual FibroScan or ultrasound to assess fibrosis progression.
• Bone‑density scan every 2‑3 years if on long‑term steroids.

Nutrition & exercise

• Aim for 150 minutes of moderate activity weekly—walking, swimming, or yoga.
• Limit added sugars and saturated fats; incorporate omega‑3 rich foods (fatty fish, flaxseed).
• Stay hydrated; avoid crash diets or very low‑calorie regimens that stress the liver.

Psychosocial support

• Consider counseling or support groups (American Liver Foundation, Autoimmune Hepatitis Association).
• Mind‑body techniques (meditation, breathing exercises) can reduce fatigue and anxiety.

Travel & daily life

• Carry a medical ID card stating “Autoimmune Hepatitis – on immunosuppressive therapy”.
• Bring a copy of recent labs and medication list when traveling.
• Avoid raw or undercooked seafood in areas with poor sanitation to prevent superimposed infection.

Prevention

Because AIH is largely driven by genetics, primary prevention is limited. However, you can reduce triggers and complications:

• Avoid medications known to provoke AIH unless clearly indicated and monitored.
• Vaccinate against hepatitis A & B, influenza, and other preventable infections.
• Limit alcohol – No more than 1 drink per day for women, 2 for men, or abstain completely if liver disease is established.
• Maintain a healthy weight – Obesity can accelerate fibrosis.
• Screen first‑degree relatives if a close family member has AIH; early detection of abnormal liver enzymes can prompt timely evaluation.

Complications

If left untreated or poorly controlled, immune‑mediated hepatitis can lead to serious outcomes:

• Cirrhosis – Occurs in 15‑30 % of patients within 10 years of onset.
• Portal hypertension – May cause variceal bleeding, ascites, or hepatic encephalopathy.
• Hepatocellular carcinoma (HCC) – Risk rises when cirrhosis develops; annual ultrasound is recommended.
• Drug toxicity – Long‑term steroids increase risk of diabetes, osteoporosis, hypertension, and cataracts.
• Infections – Immunosuppression predisposes to bacterial, fungal, or viral infections.

When to Seek Emergency Care

References

1. Mayo Clinic. Autoimmune hepatitis. Updated 2024. https://www.mayoclinic.org
2. National Institute of Diabetes & Digestive and Kidney Diseases (NIDDK). Autoimmune hepatitis. 2023. https://www.niddk.nih.gov
3. Cleveland Clinic. Autoimmune hepatitis: Diagnosis & treatment. 2024. https://my.clevelandclinic.org
4. World Health Organization. Guidelines for the management of autoimmune hepatitis. 2022. https://www.who.int
5. American Association for the Study of Liver Diseases (AASLD). 2023 Practice Guidance for AIH. https://www.aasld.org

```